Page 49 - memoria2020online
P. 49
Memoria de actividades
2020
HER2-negativo, tratadas Suppl):Abstract nr GS3-00. Alonso Romero J.L, Antón INVESTIGACIÓN Y PUBLICACIONES - Comunicaciones a Congresos
DOI:10.1158/1538-7445.SABCS20- Torres A, Carrasco E, Chen
con Palbociclib (PAL) más GS3-00 Published February 2021 J, Neuwirth R, Leonard E.J,
and Slamon D.
terapia Endocrina (TE) versus https://cancerres.aacrjournals.org/
Open-label, randomized,
Capecitabina (CAP) content/81/4_Supplement/GS3-00
phase 2 study of sapanisertib
SEOM virtual 2020. 19-23 Oral
de Octubre. SESIÓN DE (TAK-228/MLN0128) in
COMUNICACIONES: MAMA Loibl S, Marme F, Martin
AVANZADA. Número O-33 M, Untch M, Bonnefoi H, combination with fulvestrant in
Kim S, Bear H, Mc Carthy
SABCS Virtual N, Olive M.M, Gelmon K, postmenopausal women with
Symposium Garcia-Saenz J.A, Kelly
C.M, Reimer T, Toi M, Rugo estrogen receptor-positive
Oral H.S, Seiler S, Nekljudova V,
Denkert C, Gnant M, Makris (ER+)/human epidermal growth
Kalinsky K, Barlow W.E, A, Burchardi N and von
Meric-Bernstam F, Gralow Minckwitz G. factor receptor-2-negative
J.R, Albain K.S, Hayes
D.F, Lin N.U, Perez E.A, Phase III study of palbociclib (HER2-) advanced or metastatic
Goldstein L.J, Chia S.K,
Dhesy-Thind S, Rastogi P, combined with endocrine breast cancer (MBC) that
Alba E, DeLaloge S, Martin
M, Gil Gil M, Arce-Salinas C, therapy (ET) in patients with previously progressed during
Brain E, Park I.H, Pierga J,
Lluch A, Ramos Vazquez M, hormone-receptor-positive or after aromatase inhibitor
Ruiz-Borrego M, Hae Jung
K, Ferrero J, Schott A, Shak (HR+), HER2-negative primary therapy (NCT02756364)
S, Sharma P, Lew D.L, Miao
J, Tripathy D, Hortobagyi breast cancera and with high 2020 SABCS, December 8-12.
G.N, Pusztai L. Spotlight Poster Discussion 1 –
relapse risk after neoadjuvant Wednesday, December 9, 2020:
First results from a phase III 4:00 – 5:15 PM. Novel Therapeutics.
chemotherapy (NACT): First Abstract PD1-01.
randomized clinical trial of Proceedings of the 2020 San Antonio
results from PENELOPE-B Breast Cancer Virtual Symposium;
standard adjuvant endocrine 2020 Dec 8-11; San Antonio, TX.
2020 SABCS, December 8-12. Philadelphia (PA): AACR; Cancer
therapy +/- chemotherapy in General Session 1 – Wednesday, Res 2021;81(4 Suppl):Abstract nr
December 9, 2020: 9:00 AM – 12:00 PD1-01.DOI:10.1158/1538-7445.
patients (pts) with 1-3 positive PM. Abstract PGS1-02. SABCS20-PD1-01 Published
GS1-03: Discussant. Ruth O’Regan. February 2021
nodes, hormone receptor- Proceedings of the 2020 San
Antonio Breast Cancer Virtual https://cancerres.aacrjournals.org/
positive (HR+) and HER2- Symposium; 2020 Dec 8-11; San
Antonio, TX. Philadelphia (PA): content/81/4_Supplement/PD1-01
negative breast cancer with AACR; Cancer Res 2021;81(4
Suppl):Abstract nr GS1-02. Poster Discussion
recurrence score of 25 or less: DOI:
10.1158/1538-7445.SABCS20- Arpino G, de la Haba-
SWOG S1007 GS1-02 Published February 2021 Rodriguez J, Ferrero J.M,
De Placido S, Klingbiel D,
2020 SABCS, December 8-12. https://cancerres.aacrjournals.org/ Revelant V, Wohlfarth C,
General Session 3 – Thursday, Poppe R and Rimawi M.F.
December 10, 2020: 8:45 AM CT. content/81/4_Supplement/GS1-02
Abstract GS3-00. Final analysis of PERTAIN: A
Proceedings of the 2020 San Poster Discussion
Antonio Breast Cancer Virtual randomized, two-arm, open-
Symposium; 2020 Dec 8-11; San García-Sáenz J.A,
Antonio, TX. Philadelphia (PA): Martínez-Jáñez N, Martín label, multicenter phase II
AACR; Cancer Res 2021;81(4 M, Lahuerta Martínez A,
González-Santiago S, Ferrer trial assessing the efficacy and
Tur N, Ramos Vázquez M,
safety of first-line pertuzumab
given in combination with
trastuzumab plus an aromatase
inhibitor in patients with HER2-
positive and hormone receptor-
49
